Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.

By F. V. Leth, P. Phanuphak, K. Ruxrungtham, E. Baraldi, S. Miller, B. Gazzard, P. Cahn, U. Lalloo, IP van der Westhuizen, Malan* and 19 more. The Lancet, 2004

738 citations recorded by the source corpus.

Subfields: Emergency Medicine, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/ffe56954a2db51dcad14b74504d9d149cce73658

Citations in the corpus

• Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. (2004, neutral): “Age, mean (absolute range), y 36 (19-61) 36 (18-64)”